Concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma

TL;DRAbstract

Hematol Oncol Stem Cell Ther 1(2) April 2008 hemoncstem.edmgr.com 124 The incidence of nasopharyngeal carcinoma (NPC) per 100 000 male population ranges from more than 20 in the Southeast Asian population to 0.5 in the white population.1 The histot logic pattern, response to radiotherapy as well as surt vival, vary markedly among different ethnic groups.2 Nasopharyngeal carcinoma is a radiosensitive tumor and radiation therapy still remains the standard treatment. However, the results of conventional radiotherapy techt niques and fractionations are unsatisfactory, especially for patients with advanced locoregional disease.3 The 5tyear survival rates for patients with locally advanced NPC treated with radiotherapy alone are 10% to 40%.4,5 Although new radiotherapy techniques have improved 3t and 5tyear actuarial survival (75% and 56%, respect tively)6 both locoregional and distant relapse are still the main causes of failure.7 NPC is also a chemosensitive tumor and high ret sponse rates

Chat with Paper

AI Agents for this Paper